UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors

    • Categories

    Archives

    Mar

    09

    First Presentation of Year 4 BIMZELX® (bimekizumab-bkzx) Data Showed Long-Term Maintenance of Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis

    Read More Share:linkedin| twitter| email| facebook

    Jan

    11

    Our Wish in 2024: Renewed Hope for People Living with Chronic Inflammatory Diseases

    Read More Share:linkedin| twitter| email| facebook

    Nov

    14

    UCB Announces U.S. Availability of BIMZELX® for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis

    Read More Share:linkedin| twitter| email| facebook

    Oct

    18

    BIMZELX® Approved by the U.S. FDA for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis

    Read More Share:linkedin| twitter| email| facebook

    Aug

    01

    Evolving Expectations for Dermatological Conditions

    Read More Share:linkedin| twitter| email| facebook

    Dec

    23

    UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab

    Read More Share:linkedin| twitter| email| facebook

    Dec

    07

    The Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic Arthritis

    Read More Share:linkedin| twitter| email| facebook

    Nov

    22

    UCB Submits Response to FDA Complete Response Letter for Bimekizumab

    Read More Share:linkedin| twitter| email| facebook

    Sep

    07

    New Three-Year Bimekizumab Data Reinforce Long-Term Maintenance of Complete Skin Clearance in Moderate to Severe Plaque Psoriasis

    Read More Share:linkedin| twitter| email| facebook

    Sep

    01

    UCB Showcases Strength of the Expanding Dermatology Portfolio at the 31st EADV Congress

    Read More Share:linkedin| twitter| email| facebook

    © 2009 - 2020 UCB, Inc., Atlanta. All rights reserved.
    USPR-CORP-0115-00003(2)